These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2030884)

  • 21. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source.
    Rhea S
    Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA's enforcement of IRBs and patient informed consent.
    Kelsey FO
    Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627
    [No Abstract]   [Full Text] [Related]  

  • 24. ECRI comments on FDA's reuse plan.
    Healthc Hazard Manage Monit; 2000 Jun; 13(10):4-5. PubMed ID: 11125912
    [No Abstract]   [Full Text] [Related]  

  • 25. No dillydallying: Barton. Proposed legislation in response to GAO report on FDA's slow debarment.
    Rhea S
    Mod Healthc; 2009 Oct; 39(43):12-3. PubMed ID: 19972653
    [No Abstract]   [Full Text] [Related]  

  • 26. Women's health advocates dismayed at FDA's Plan B decision.
    Ready T
    Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
    Merkatz RB
    J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA's new rule on treatment use and sale of investigational new drugs.
    Levine RJ
    IRB; 1987; 9(4):1-4. PubMed ID: 11649946
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA new drug approvals in 2009.
    Wynn RL
    Gen Dent; 2010; 58(4):280-4. PubMed ID: 20591770
    [No Abstract]   [Full Text] [Related]  

  • 30. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 31. DSHEA provisions confine FDA's authority to issue regulations that concern allegedly adulterated dietary supplements.
    McNamara SH; Siegner AW; Phelps EP
    Food Drug Law J; 1999; 54(4):595-8. PubMed ID: 11824456
    [No Abstract]   [Full Text] [Related]  

  • 32. Pediatric drug trials. Challenge to FDA's authority may end up giving it more.
    Marshall E
    Science; 2002 May; 296(5569):820-1. PubMed ID: 11988539
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA's emergency research rule: an inch given, a yard taken.
    Gillenwater GE
    Food Drug Law J; 2008; 63(1):217-56. PubMed ID: 18561460
    [No Abstract]   [Full Text] [Related]  

  • 34. Can (or should) the IRB assume the FDA's functions at early stages of the IND process?
    Levine RJ
    IRB; 1981 Dec; 3(10):4-5. PubMed ID: 11649414
    [No Abstract]   [Full Text] [Related]  

  • 35. Old, new, and not new drugs.
    Knobloch CP
    J Am Vet Med Assoc; 1979 Oct; 175(7):698. PubMed ID: 528312
    [No Abstract]   [Full Text] [Related]  

  • 36. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities.
    Kelly DP; Bachorik LL
    Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741
    [No Abstract]   [Full Text] [Related]  

  • 37. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
    Aziz KJ; Sliva CA; Gutman SI
    Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
    [No Abstract]   [Full Text] [Related]  

  • 38. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 39. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 40. The evolution of substantial equivalence in FDA's premarket review of medical devices.
    Goldberger BA
    Food Drug Law J; 2001; 56(3):317-37. PubMed ID: 11944642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.